MedTrace Logo

A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Condition

NCT05781113 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2026-03-20

No results posted yet for this study

Summary

To measure the effectiveness of a Remote Patient Monitoring solution based on the use of a smart insole wearable device (and associated smart phone app), for monitoring MS patients' condition on a day-to-day basis. The main focus is the objective measurement of gait, given that 75% of people with MS display clinically significant gait impairments. Initial gait lab "gold standard" data indicate that the Artificial Intelligence (AI)-based digital biomarker will prove to be highly effective at detecting changes in the MS patient's condition.

Conditions

Sponsors & Collaborators

  • University of Ottawa

    collaborator OTHER

  • Barts & The London NHS Trust

    collaborator OTHER

  • The Ottawa Hospital

    collaborator OTHER

  • Brigham and Women's Hospital

    collaborator OTHER

  • Celestra Health Systems

    lead INDUSTRY

Principal Investigators

  • Gauruv Bose, Dr. · The Ottawa Hospital

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2026-11-01
Completion
2026-12-31

Countries

  • United States
  • Canada
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05781113 on ClinicalTrials.gov